As of November 6, 2026, Day One Biopharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 23, 2026 (Form 8-K, April 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Day One Biopharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Day One Biopharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-23. Every row below is cited to the filing it comes from, and this page adds each new change as Day One Biopharmaceuticals, Inc. files it.
Also on the record for Day One Biopharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | — | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Atlas Venture Fund XI, L.P. | — | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13D/A, by AI Day1 LLC | — | 5%+ stakes | Source |
| April 13, 2026 | Stake report, Schedule 13D/A, by AI Day1 LLC | 12.52% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | — | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 19, 2026 | Stake report, Schedule 13G, by Glazer Capital, LLC | 5.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Vestal Point Capital, LP | 5.1% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.6% of the class | 5%+ stakes | Source |
| January 6, 2026 | Acquired Mersana Therapeutics, Inc. | $128.80M | Acquisition | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Day One Biopharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Day One Biopharmaceuticals, Inc. and the records around it.
Day One Biopharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- Atlas Venture Fund XI, L.P. also filed stake reports on 3 other companies: DYNE THERAPEUTICS, INC. (Aug 2026), Korro Bio, Inc. (Aug 2026), SIONNA THERAPEUTICS, INC. (Oct 2025)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Day One Biopharmaceuticals, Inc.
Get an email when Day One Biopharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Day One Biopharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Day One Biopharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Day One Biopharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-23 | Reported | not named in the filing | 8-K, 2026-04-23 |
New leaders reset buying decisions — get the Full Report on Day One Biopharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Day One Biopharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Day One Biopharmaceuticals, Inc.Every change, in the filing's words
Reported
These departures were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices.
- Pursuant to the Merger Agreement, as of the Effective Time, the directors of Purchaser immediately prior to the Effective Time became the directors of the Surviving Corporation.
- The directors of Purchaser immediately prior to the Effective Time were David K. Lee and Danielle Button.
- As of the Effective Time, Jeremy Bender, Habib Dable, Scott Garland, William Grossman, Natalie Holles, John Josey, Garry Nicholson and Saira Ramasastry each ceased to be directors of the Company and members of any committee of the Company's board of directors.
- Pursuant to the Merger Agreement, as of the Effective Time, the officers of Purchaser immediately prior to the Effective Time became the officers of the Surviving Corporation.
- The officers of Purchaser immediately prior to the Effective Time were David K. Lee as President and Secretary, and Danielle Button as Treasurer.
- Effective immediately following the Effective Time, all of the incumbent officers of the Company, as of immediately prior to the Effective Time, were removed as officers of the Company.
Tools for this story
Each opens in a new tab, filled in for Day One Biopharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.